Kelly Baden, Guttmacher vice president for public policy, breaks down the latest updates in Louisiana v. FDA, including what’s at stake for patients and providers nationwide.
To find care, head to PlanCPills.com or iNeedAnA.com.
What's at stake in Louisiana v. FDA
Video
Transcript: The biggest threat to abortion access since the Dobbs decision is playing out in the courts right now.
On Friday, the Fifth Circuit ruled to temporarily block mifepristone via telehealth for patients across the country, not only in states where abortion is banned and restricted. Today, the Supreme Court temporarily paused Friday's ruling, but this only lasts until May 11th. The court could still allow the Fifth Circuit's ruling to go into effect, once again cutting off telehealth access to mifepristone for people across the country.
Let's be clear. This case relies on false narratives and junk science, not on evidence. Decades of research show that mifepristone is safe and effective, and that this is true whether someone gets the pills from a clinician in person or in the mail.
The need for abortion care remains unchanged despite these attacks, and providers and patients once again are proving to be incredibly resilient. But each new restriction adds a layer of confusion and chaos, preventing many from getting the care that they need. Patients should not have to navigate these ever-changing legal and policy restrictions.
Everyone deserves access to their preferred method of abortion care, whether that be at home via telehealth or in person at a clinic. To find care, head to PlanCPills.com or INeedAnA.org.